Q-omics provides the consensus-scored RAB4B profile across patient tissues and cancer cell-line models. RAB4B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB4B is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, RAB4B RNA expression shows 18,288 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where RAB4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB4B survival associations across molecular data types. RAB4B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB4B RNA expression–survival associations across cancer types. High RAB4B expression shows unfavorable associations in KIRC, ACC and UVM, but favorable associations in CESC, HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB4B RNA expression.
This table summarizes RAB4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RAB4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB4B shows lower tumor expression in COAD and KICH and higher tumor expression in LIHC, KIRC, BRCA and BLCA. The COAD box plot shows higher RAB4B RNA expression in normal versus tumor tissue (log2 FC = −0.670, t-test p < 0.001).
This table shows molecular features associated with RAB4B in patient tissues and cancer cell lines. In patient samples, RAB4B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SKIN.
